Nextgen Ventures

J.P. Morgan's latest research on the medtech Industry reveals some interesting datapoints on venture investment and deal-making across the sector. The dollar value of venture investment surpassed 2023 mainly due to larger deals, while M&A both exceeds value as well as deal number since record year 2021. Have a look into the report for the more detailed findings. #venturecapital #impactinvestment #medtech

A significant development at Sirius Medical! We are excited to see their partnership with Mammotome come to life. This expands access to the innovative breast cancer care technology for doctors and women, enabling earlier and more precise treatment. We extend our congratulations to the team and look forward to what the future holds! #medtech #innovation #impact #investing Bram Schermers

Next month we will be attending the below events. We're looking forward to connect with founders, investors, experts and innovators. 1️⃣ imec Belgian HealthTech Night – March 11 2️⃣ HealthValley - March 13 3️⃣ SuperNova – March 26 and 27 4️⃣ Philips Innovation Award Investor Day – March 28 Are you attending any of these? Drop us a message. #venturecapital #impactinvesting #startups #innovation #investment

We’re happy to announce that Julian Gansen has joined NextGen Ventures as a venture partner. As an external market access expert, Julian will provide significant value to our portfolio companies by helping them navigate the German market. Julian brings specialized expertise in market access, commercial strategy & operations, and M&A, along with a strong network within the German ecosystem from his roles at Sidekick, Mementor and Newsenselab. His deep understanding of the German healthcare and tech landscape will help our portfolio companies to accelerate further. #team #medtech #healthIT #germany #venturecapital #innovation

🚀 Exciting News from Sirius Medical! On #WorldCancerDay, we’re happy to announce €10M in scale-up funding led by Invest-NL and Nextgen Ventures with support from De Groot Family Office, BOM (Brabantse Ontwikkelings Maatschappij), Holland Capital, Curie Capital BV, and more. “We are proud of the Sirius Medical team and grateful for the trust of our investors. This investment enables us to continue making a meaningful difference for women with breast cancer,” says Bram Schermers, CEO of Sirius Medical, "And this is just the beginning, we have more exciting news coming up soon." This investment enables Sirius Medical to enhance the #Pintuition Surgical Marker Navigation platform and extend our global reach to new markets. Read the full press release here: https://hubs.li/Q0358KhJ0 🌐#HealthcareInnovation #BreastCancerCare #SiriusPintuition #WorldCancerDay European Society of Surgical Oncology (ESSO) iBRA-NET AWOgyn The American Society of Breast Surgeons iBreastBook

Go van Dam was asked to tell about the potential of TRACER, a company that we support since 2019. The team accelerates clinical trials by generating early in-human data on drugs by means of nuclear imaging. Their use of nuclear imaging requires only microdoses of drugs for initial assessment of toxicity and effectiveness in a so-called phase 0 study. The impact? Faster and more effective drug development, ultimately delivering better treatments to patients. Interested to learn more? Read the article that shows the mission, technology and potential of TRACER in more detail. Ari Aminetzah, MBA Go van Dam #innovation #venturecapital #nuclearimaging

“It’s all about the caregivers. If they can work with joy and confidence, we’ve achieved our mission (Menno Gravemaker, Momo Medical).” Read about how Momo Medical embraced the challenge of creating a product that not only supports nursing home residents but truly makes a difference for caregivers and how Momo Medical was able to scale from 100 to 10,000 deployed units in just two years. Also, learn about the role of NextGen Ventures which became a key investor in Momo Medical alongside PGGM, Fundis, InnovationQuarter, Rabobank, Noaber and several other investors. #innovation #healthcare #impactinvesting #venturecapital

Exciting news at NextGen Ventures!   We're happy to welcome Meike Bomhof as our new Market Access & Reimbursement Advisor. Meike brings a wealth of experience from industry roles in leading companies like Baxter, Edwards Lifesciences and Abbott as well as through her strategic medtech market access consulting expertise gained over the last two decades at Avania (formerly Hull Associates) and various medtech accelerators such as EIT Health and Techleap.   In her new role, Meike will support our portfolio companies navigate market access and reimbursement challenges while also contributing to the assessment of potential investments. Her unique insights and passion for an early market access strategy are sure to be beneficial for startups in our ecosystem.   As Meike wisely puts it: "Startups should initiate research into a market & reimbursement strategy for their innovation much earlier, as this increases speed to optimal market adoption significantly."   Welcome to the team, Meike! #venturecapital #impactinvesting #medtech #investments #venturepartner

Het Financieele Dagblad highlights the funding challenges for Dutch medical startups that inhibits the startups to realize their potential. This requires us, as Peter Haasjes puts it in the article, to look for follow-up financing before we invest into a startup. We note a mindset shift from gathering clinical data to later-stage market access and reimbursement, effectively resulting in increased interest for companies with revenue in the United States. The key reasons for this are: 1️⃣ The introduction of the MDR which makes obtaining a CE-mark for medical devices more difficult as the process is lengthy and less transparent compared to the FDA. 2️⃣The differences in national reimbursement systems within the European Union. 3️⃣The M&A landscape shift towards primarily acquiring revenue generating companies. Despite the challenges, we see great potential as Europe has tremendous academic ecosystem that drives advancements in regenerative medicine, minimally invasive surgical technologies, and AI. These innovations promise to transform healthcare by extending life and improving efficiency. Still, success requires a clear understanding of the reimbursement landscape, a strong ‘go-to-market’ strategy and solid plans for funding through sales or fundraising. We’re excited to engage with companies that align with this vision and discuss strategies to bring these technologies to life. One thing is sure, the article written by Maarten van Poll drives engagement. In case you want to see further comments and insights by the eco-system, we recommend you to dive into the comments of a post made by Rinke Zonneveld. #investing #medicaltechnology #medtech #impact #venturecapital #healthcare

December 10th we pitched at the HealthTech Investor Summit in Bruges Belgium. Our technology and business approach was well received by investors and peer startups. IMPLICAN B.V. Ivo Kooijman Klaas Havenga #htis2024 #colorectal #surgery